Riskpilot← Back to searchSign inGet full accessNordic Pharma Consulting ApS
APSActiveCVR 37368598Ullasvej 7BBusiness and other management consultancy activities · NACE 7020Est. 201611 employees
Revenue 2025
DKK 15,9M
+13% vs 2024
EBITDA margin
29.9%
+25% vs 2024
Equity ratio
56.6%
Financial strength
Net profit 2025
DKK 3,7M
+24% vs 2024
| Revenue | DKK 15,9M | +13% |
| EBITDA | DKK 4,7M | +25% |
| Net profit | DKK 3,7M | +24% |
| Total assets | DKK 7,9M | -3% |
| Equity | DKK 4,5M | +19% |
| Employees | 11 | — |
Legal name
Nordic Pharma Consulting ApS
CVR number
37368598
Legal form
Anpartsselskab
NACE code
7020 · Business and other management consultancy activities
Founded
14. januar 2016
Share capital
DKK 50.000
Employees
11 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af 1 direktør.
Company purpose
Selskabets formål er at drive konsulentvirksomhed indenfor produktion og logistik.
Address
Ullasvej 7B
Phone
+4523645858
Email
bill@nordicpharmaconsulting.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.693 | 5.989 | 6.963 | 8.595 | 8.896 | 8.841 | 11.622 | 11.213 | 14.102 | 15.902 |
| Staff expenses | -895 | -4.963 | -6.320 | -7.620 | -6.921 | -6.470 | -6.960 | -9.165 | -10.289 | -11.152 |
| EBITDA | 797 | 1.026 | 643 | 974 | 1.975 | 2.371 | 4.662 | 2.048 | 3.813 | 4.750 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 797 | 1.026 | 643 | 974 | 1.975 | 2.371 | 4.662 | 2.048 | 3.813 | 4.750 |
| Net financials | -0 | -10 | -6 | -7 | -18 | -27 | -42 | 7 | 13 | -4 |
| Profit before tax | 797 | 1.016 | 638 | 967 | 1.957 | 2.344 | 4.620 | 2.055 | 3.826 | 4.746 |
| Tax | 178 | 230 | 145 | 215 | 437 | 524 | 1.025 | 466 | 860 | 1.061 |
| Net profit | 620 | 785 | 493 | 752 | 1.520 | 1.820 | 3.595 | 1.589 | 2.966 | 3.685 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.313 | 2.394 | 2.329 | 2.231 | 4.623 | 5.053 | 10.180 | 5.207 | 8.146 | 7.927 |
| Equity | 670 | 855 | 748 | 803 | 2.322 | 2.623 | 4.397 | 2.391 | 3.769 | 4.487 |
| Long-term debt | 0 | 0 | 500 | 300 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 644 | 1.539 | 1.081 | 1.128 | 2.300 | 2.430 | 5.783 | 2.815 | 4.377 | 3.440 |
| Total debt | 644 | 1.539 | 1.581 | 1.428 | 2.300 | 2.430 | 5.783 | 2.815 | 4.377 | 3.440 |
EBITDA margin
29.9%
This company
15.8%
Market median
+89% vs market
20162025
Equity ratio
56.6%
This company
38.2%
Market median
+48% vs market
20162025
Return on equity
82.1%
This company
18.4%
Market median
+346% vs market
20162025
Net profit margin
23.2%
This company
8.1%
Market median
+186% vs market
20162025
Asset turnover
2.01×
This company
1.12×
Market median
+79% vs market
20162025
Debt / equity
0.77×
This company
0.62×
Market median
+24% vs market
20162025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-14 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RD Management | Management | 2019 | — | — |
TB Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Bill Holding ApS | Company | 50.0% | 50.0% | 2016 |
by.david ApS | Company | 33.3% | 33.3% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Bill Holding ApS
Nordic Pharma Consulting ApS Board members of Nordic Pharma Consulting ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ray David Sossna | Management | 0 companies |
| Thomas Bill Madsen | Chief Executive Officer | 0 companies |